# KLOW Peptide — Four-Ink Research Record | KLOW Order

> KLOW peptide is four research compounds in one vial: BPC-157, TB-500, GHK-Cu, and KPV. Four mechanistically distinct programs, one lyophilized blend. Here is what the studies measured.

BPC-157 drives angiogenesis via VEGFR2. TB-500 accelerates cell migration via actin sequestration. GHK-Cu remodels the extracellular matrix at the gene level. KPV blocks NF-kB at the nucleus. The KLOW peptide research record, set in order.

## What Is KLOW Peptide?

KLOW peptide is a four-compound lyophilized research blend: BPC-157 (10 mg), TB-500 (10 mg), GHK-Cu (50 mg), and KPV (10 mg), totaling 80 mg per vial [25]. The formulation stacks four peptides whose preclinical records cover overlapping but mechanistically distinct research programs — angiogenesis and tissue repair (BPC-157), cell migration and wound closure (TB-500), collagen and extracellular matrix remodeling (GHK-Cu), and NF-kB-mediated inflammation control (KPV) [1][7][11][14].

Each component has its own published literature. No controlled in-vivo study examines the four-peptide combination. What KLOW peptide represents in the research context is four independently studied mechanisms assembled into one preparation — four spot inks, each its own physical layer, overprinted on a single research page.

GHK-Cu at 50 mg is the mass-dominant component by a wide margin — five times the dose of each other peptide. Its role as the dominant ink is not arbitrary: GHK-Cu activates approximately 4,000 human genes relevant to tissue remodeling and collagen synthesis [11][12], making it the broadest genomic input in the blend.

BPC-157 at 10 mg contributes the angiogenesis and gut-protective arm. Across more than a decade of rodent studies, BPC-157 consistently upregulates VEGFR2 expression and activates the VEGFR2-Akt-eNOS signaling axis [1][2], accelerates tendon-to-bone healing [4][23], and demonstrates mucosal cytoprotection with clinical trial eligibility [5].

TB-500 at 10 mg delivers the actin-sequestration arm. Thymosin beta-4, the parent protein of the synthetic TB-500 fragment, drives cell migration and reepithelialization — 42% faster wound closure at day 4 and 61% by day 7 in rat wound models [8].

KPV at 10 mg is the NF-kB brake. This C-terminal tripeptide fragment of alpha-MSH blocks p65 RelA nuclear translocation via competitive inhibition of importin-alpha3, measurably reducing TNF-alpha-induced IL-8 secretion in bronchial epithelial cells [15] and cutting disease severity in murine colitis models at nanomolar concentrations [16].

## The KLOW Peptide Blend: Four Compounds, One Protocol

The KLOW peptide blend is not a compound — it is a protocol in lyophilized form. Each peptide brings a different published mechanism to the same vial [25].

BPC-157 is a 15-amino-acid pentadecapeptide (1419.5 Da) isolated from human gastric juice. Its VEGFR2 upregulation and nitric oxide modulation have been reproduced across rat tendon, ligament, muscle, and gut injury models [1][2][4][5][23]. Three small human pilot studies — knee pain, interstitial cystitis, and pharmacokinetics — reported no adverse effects, though the compound remains investigational [19].

TB-500 is the synthetic Ac-LKKTETQ heptapeptide fragment of thymosin beta-4, the major actin-sequestering molecule in mammalian cells [7][9]. The full-length thymosin beta-4 protein has driven multicenter clinical trials for corneal and dermal wound repair [7]; TB-500 replicates the actin-binding, cell-migration, and anti-scarring activity at a fraction of the molecular weight [9].

GHK-Cu is glycyl-L-histidyl-L-lysine complexed with copper(II). Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 [26]. In human fibroblast cultures, GHK-Cu stimulates collagen synthesis beginning at 10^-12 M and maximizing at 10^-9 M [10]. A 2025 study extended GHK-Cu's research applications into gut mucosal inflammation, showing SIRT1/STAT3 pathway modulation and restoration of tight junction proteins ZO-1 and Occludin in a murine colitis model [recent_1].

KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-MSH (342 Da). It retains the anti-inflammatory activity of the parent hormone without the pigmentation side effects [18]. Its transport via PepT1 into intestinal epithelial and immune cells is upregulated in inflamed colon tissue, which may enhance KPV uptake specifically at inflamed sites [16][17].

## What Is the KLOW Blend?

The KLOW blend contains: GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — 80 mg total per lyophilized vial [25]. The 50 mg GHK-Cu mass share means collagen and matrix biology drives the majority of the blend's weight. The three minority peptides bring complementary tissue-repair, angiogenic, and anti-inflammatory mechanisms.

Where KLOW diverges from the Wolverine stack (BPC-157 + TB-500 alone) is in the addition of GHK-Cu's genomic-scale matrix remodeling and KPV's hard NF-kB block. Where KLOW diverges from GLOW-type blends (which typically emphasize GHK-Cu + longevity peptides) is in BPC-157's gut and tendon repair profile and KPV's innate immune modulation [25].

No published preclinical or clinical study examines the four-peptide KLOW combination directly. The blend research context is built from the four individual literatures, extrapolated from complementary mechanisms rather than empirical co-administration data.

## What Does the KLOW Peptide Do?

The KLOW peptide blend covers four mechanistic domains that individual-compound studies have characterized separately:

BPC-157 promotes angiogenesis through VEGFR2 upregulation, accelerates tendon-to-bone healing at 10 μg/kg/day in rats [4], and demonstrates gut mucosal cytoprotection that has reached clinical trial stage (PL 14736, Pliva, Croatia) [5]. A 2025 narrative review confirmed the VEGFR2/Akt-eNOS mechanism and classified the compound as investigational pending well-designed human trials [19].

TB-500 (the Ac-LKKTETQ fragment of thymosin beta-4) accelerates reepithelialization by 42% at day 4 and 61% at day 7 in rat wound models [8], reduces myofibroblast numbers to limit scar formation, and promotes new blood vessel formation across dermal, corneal, and cardiac models [7][9].

GHK-Cu modulates expression of approximately 4,000 human genes — 59% upregulated, 41% suppressed — including pathways for collagen synthesis, anti-inflammatory action, and COPD fibroblast restoration [12]. A collagen dressing containing GHK produced a 9-fold increase in collagen production in rats [12].

KPV rescued all animals from death during DSS colitis in mice lacking functional MC1R receptors, demonstrating an MC1R-independent mechanism [14]. Oral KPV reduced disease severity in both DSS- and TNBS-induced colitis models via PepT1-mediated uptake [16].

See the [KLOW peptide benefits](/benefits) page for more on what each component's research record covers across specific tissue types.

## What Is the KLOW Peptide Used For in Research?

Preclinical research on KLOW's four components covers several overlapping biological domains:

**Tissue repair and angiogenesis.** BPC-157 has accelerated Achilles tendon healing with improved biomechanical properties and collagen organization [4], medial collateral ligament healing over a 90-day study period in rats [23], and bone and muscle healing across multiple models [2]. TB-500 accelerates wound reepithelialization and reduces fibrosis [7][8].

**Collagen and extracellular matrix remodeling.** GHK-Cu is the dominant KLOW component by mass and the primary driver of collagen biology. GHK-Cu-liposomes shortened wound healing time to 14 days in a murine scald model with a 33.1% increase in cell proliferation and elevated VEGF and FGF-2 [13].

**Gut and mucosal inflammation.** BPC-157 has been studied in rodent IBD models at oral and intraperitoneal doses with anti-ulcer and mucosal healing results [5]. KPV at nanomolar oral concentrations reduced colitis severity in DSS and TNBS murine models [16]. A 2025 study showed GHK-Cu alleviates DSS-induced ulcerative colitis via SIRT1/STAT3 pathway modulation [recent_1].

**Inflammatory modulation.** KPV blocks NF-kB nuclear translocation at concentrations ≥ 1 μg/mL in bronchial epithelial cell cultures, reducing IL-8 secretion [15]. In murine IBD models, KPV-treated mice showed measurably reduced myeloperoxidase activity [14].

See [how the four peptides work together](/research#synergistic-mechanisms) and [KLOW peptide dosage](/dosage) for the preclinical dose and route data.

---

Four spot-ink literatures, one dark-stock page — editorial summaries of what the peer-reviewed studies actually printed, held by no clinic and sold by no one.